Edition:
United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

3.81USD
23 Jan 2017
Change (% chg)

$0.04 (+0.93%)
Prev Close
$3.77
Open
$3.77
Day's High
$3.83
Day's Low
$3.75
Volume
30,641
Avg. Vol
1,274,233
52-wk High
$7.49
52-wk Low
$2.61

AGEN.O

Chart for AGEN.O

About

Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to... (more)

Overall

Beta: 2.51
Market Cap(Mil.): $327.99
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  AGEN.O Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -1.35 -- --
ROI: -65.75 -1.38 14.86
ROE: -417.20 -1.07 16.28

BRIEF-Agenus files for offering of up to 157,513 shares by selling stockholder

* Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing Source text: (http://bit.ly/2jIMpis) Further company coverage:

Jan 20 2017

BRIEF-Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

* Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

Jan 17 2017

BRIEF-Agenus reports Q3 loss per share $0.47

* Agenus reports third quarter financial results and recent highlights

Oct 27 2016

BRIEF-Agenus Q2 loss per share $0.33

* Agenus reports second quarter 2016 financial results and operational progress

Jul 28 2016

Earnings vs. Estimates